Source author record

Paul Harari

Paul Harari appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

2works
1topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2022arXiv

Validation of Monte Carlo Iodine-131 radiopharmaceutical dosimetry workflow using a 3D printed anthropomorphic head and neck phantom

Purpose: In this study, we present the creation of an anthropomorphic, head and neck, nuclear medicine phantom and its characterization for the validation of a Monte Carlo, SPECT image based, Iodine-131 RPT dosimetry workflow. Methods: 3D printing techniques were used to create the anthropomorphic phantom from a patient CT dataset. Three Iodine-131 SPECT/CT imaging studies were performed using a homogeneous, Jaszczak, and an anthropomorphic phantom to quantify the SPECT images. The impact of collimator detector response (CDR) modeling and volume-based partial volume corrections (PVC) upon the absorbed dose was calculated using an image based, Geant4 Monte Carlo RPT dosimetry workflow and compared against a ground truth scenario. Finally, uncertainties were quantified in accordance with recent EANM guidelines. Results: The 3D printed anthropomorphic phantom was an accurate re-creation of patient anatomy including bone. The extrapolated Jaszczak recovery coefficients were greater than that of the 3D printed insert (~22.8 ml) for both the CDR and non-CDR cases. Utilizing Jaszczak phantom PVCs, the absorbed dose was underpredicted by 0.7% and 4.9% without and with CDR, respectively. Utilizing anthropomorphic phantom RCs overpredicted the absorbed dose by 3% both with and without CDR. All dosimetry scenarios that incorporated PVC were within the calculated uncertainty of the activity. The uncertainties in the cumulative activity ranged from 25.6% to 113% for Jaszczak spheres ranging in volume from 0.5 ml to 16 ml. Conclusion: The accuracy of Monte Carlo-based dosimetry for Iodine-131 RPT in head and neck cancer was validated with an anthropomorphic phantom. Future applications of the phantom could involve 3D printing and characterizing patient specific volumes for more personalized RPT dosimetry estimates.

preprint2015arXiv

Dosimetric and Biologic Differences in Flattened and Flattening-Filter-Free Beam Treatment Plans

Purpose: To quantitatively compare the dosimetric and biologic differences in treatment plans from flattened and flattening-filter-free (FFF) beam for three anatomic cancer sites. Methods and Materials: Treatment plans with static intensity-modulated radiotherapy beams and volumetric modulated arc therapy beams were generated for 13 patients for both the flattened beam and the FFF beam of the TrueBeam system. Beam energies of 6 MV and 10 MV were chosen for planning. A total of 104 treatment plans were generated in 13 patients. In order to analyze the biological effectiveness of treatment plans, dose volume histograms (DVH) were utilized. Flattened and FFF beam plans are quantitatively compared. Results: In head and neck cases, for VMAT plans, dose reduction in the FFF beam plans compared to the flattened beam in left cochlea, right submandibular gland and right parotid gland reached up to 2.36 Gy, 1.21 Gy and 1.45 Gy, respectively. Similarly, for static IMRT plans, the dose reduction of the FFF beam plans compared to the flattened beam plans for the same organs reached up to 0.34 Gy, 1.36 Gy and 1.46 Gy, respectively. Overall, for head and neck, the FFF beam plans achieved mean dose reduction of up to 5%, 7% and 9%, respectively for above organs at risk. For lung and prostate cases, the FFF beams provided lower or comparable NTCP values to organ-at-risk (OAR) compared to the flattened beam for all plans. Conclusions: In general, we observed treatment plans utilizing FFF beams can improve dose sparing to OARs without compromising the target coverage. Significant dose sparing effect is obtained for head and neck cancer cases, especially for the cases with relatively large field sizes (about 16x20 cm^2). For lung and prostate cases, compared to the flattened beam, the FFF beam based treatment plans provide lower or comparable dose to most OARs.